CA 125 half-life in ovarian cancer: a multivariate survival analysis

Abstract

Summary Serum CA 125 regression after cytoreductive surgery and during the first three courses of chemotherapy was studied in 60 ovarian cancer patients and compared to known prognostic factors.Various methods reported in the literature to calculate a CA 125 half-life value were compared. Using two exponential regression models (Van der Burg et al., 1988;Buller et al., 1991), mean half-lives in stage I-II patients after complete cytoreductive surgery were respectively 10.7 days (range: 5-23) and 9.8 days (range: 7-15). Within stage III-IV patients, a significant positive correlation was seen between survival and (a) stage III (P = 0.002), (b) residual tumour 1 cm (P = 0.02), (c) CA 125 normalisation after three courses (P = 0.003) and (d) CA 125 half-life < 20 days (P = 0.02-0.004, depending on the method used for half-life calculation).The median survival times of patients with and without a CA 125 normalisation after three courses were 27 and 14 months respectively (P = 0.003). When

Clinical and technical evaluation of the ACS:OV serum assay and comparison with three other CA125-detecting assays

“…The CA125 antigen became an established marker, nowadays commonly used in gynaecological practice for management of patients with ovarian cancer. 2,3 In the original Centocor CA125 assay (Fujirebio Diagnostics, Malvern, USA), a homologous doubledeterminant assay, the OC125 MAb was used both as capture and tracer antibody. Therefore, repetition of the antibody-de¢ned epitope on the CA125 antigen is mandatory for binding and detection.…”

The plasma kinetic of tumor biomarkers: experience of the Oran EHU

“…This demand is at the basis of the development of biological markers of cancer called tumor markers (TM) [2,10,11]. The range of measurable tumor markers expand day by day, although some of them are not discriminative of a benign or malignant process, their utility remains considerable in the assessment of therapeutic effect and the surveillance of the disease evolution after treatment [10,8,11,12]. The Interpretation of the serum levels of TM is based on the kinetics' notion is more sensitive and relevant than that based on the static threshold [5,9,11], the later value of which is neither adapted to the nature of the treatment nor the precocity of the signal even the assay reagents used as well.…”

“…The use of tumor markers remains essential in the detection and following of the disease evolution [8,11,12] . However, the interpretation of these serum levels based on a single value does not make it possible to evaluate either the efficacy of the treatments or the resistance of the tumor [4,5,9,10,11], henceforth the benefit of the use of a relevant method based on the " Study of the kinetics of the tumor markers [5,10,11] which makes it possible to ensure both a maximum of therapeutic efficacy and a minimum biological reagents use and the cancer chemotherapy whose cost remains very expensive.…”

“…Within this study, "CHADOU TUMOR MARKER KINETIC" or CHA-TM KINETIC software was developed by Dr H. CHADOU. It allows automatically plotting the tumor marker evolution curves within time function [3,10,11], as well as the calculation of the biological parameters associated with each marker (initial concentration, apparent half-life [7,8,11], nadir, doubling time) [1,4,8,410,11,12]. …”

Time course of carcinoembryonic antigen after resection of lung cancer: A predictor of recurrence

“…When serum tumor marker levels do not normalize after treatment, the existence of residual tumor cells is strongly suspected. [1][2][3][4][5][6] After surgical resection of tumors, serum tumor marker levels decrease in accordance with their individual elimination kinetics to a certain plateau level, [6][7][8][9][10] which is determined by the amount of postoperative tumor marker-producing cells remaining. These remaining tumor marker-producing cells may consist in part of residual tumor cells when the plateau level is higher than the normal range.…”